Withdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment Trial

Withdrawal of nucleos(t)ide analog therapy is increasingly being evaluated in chronic hepatitis B infection as a strategy to induce hepatitis B surface antigen (HBsAg) loss. The Hepatitis B Research Network Immune-Active Trial evaluated treatment with tenofovir (TDF) for 4 years ± an initial 6 month...

Descripción completa

Detalles Bibliográficos
Autores principales: Feld, Jordan J., Wahed, Abdus S., Fried, Michael, Ghany, Marc G., Di Bisceglie, Adrian M., Perrillo, Robert P., Khalili, Mandana, Yang, Xue, Belle, Steven H., Janssen, Harry L.A., Terrault, Norah, Lok, Anna S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298187/
https://www.ncbi.nlm.nih.gov/pubmed/36728214
http://dx.doi.org/10.14309/ajg.0000000000002176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298187/
https://www.ncbi.nlm.nih.gov/pubmed/36728214
http://dx.doi.org/10.14309/ajg.0000000000002176

Ejemplares similares